Operational Update

Prima BioMed Becomes Immutep

Prima Secures European Patent Grant for Lead Product IMP321 in Cancer

FAQ - Change of company name from 'Prima BioMed Limited' to 'Immutep Limited'

Prima BioMed Changes its Name to Immutep Ltd

Eftilagimod Alpha (LAG-3Ig or IMP321) Pre-IND Meeting with the FDA

New Eftilagimod Alpha (LAG-3Ig or IMP321) Data for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting

Dr. Frédéric Triebel Presented at the World Immunotherapy Congress 2017

Dr. Frédéric Triebel presenting at the World Immunotherapy Congress 2017

IMP321 New Data Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting

Prima Secures Japanese Patent Grant for IMP731 Antibody

Prima Secures Japanese Patent Grant for Lead Product IMP321 in Infectious Disease

Prima BioMed and Monash University Receive Funding Grant for LAG-3 Research Project

Prima BioMed Appoints Non-Executive Director to the Board

Prima BioMed Receives A$1.3 Million Tax Refund from French Government

Financial Update 2H17

Prima BioMed Announces Second Milestone Payment for IMP701 Program

Prima BioMed Announces Approval for the Initiation of the ‘INSIGHT’ Clinical Trial

Prima BioMed Announces Pricing of US$5.0 Million Registered Direct Offering of Its American Depositary Shares

Operational Update

ASCO Poster 2017

LAG-3Ig (IMP321) demonstrates positive Safety and Efficacy Qualities in Breast Cancer Clinical Trial

Prima BioMed Announces Formation of Clinical Advisory Board

Data from Prima BioMed AIPAC Clinical Trial to be Presented at 2017 ASCO Conference

Prima BioMed Receives Approval for Third Cohort of Phase I Melanoma Trial

Prima BioMed receives A$492,144 Tax Refund from Australian Government

Prima BioMed Completes Recruitment for Second Patient Cohort in Melanoma Trial and Will Present at ICI Conference in Boston

USA Patent Grants for IMP321 in Cancer

First Half 2017 Operational Update

Prima BioMed Receives ~A$860,000 Tax Credit Payment from French Government

Prima BioMed to Present at 2nd Annual Cancer Immunotherapy Conference

Prima BioMed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer

Prima BioMed to Maintain NASDAQ Listing

Prima BioMed Commences Recruitment for Second Cohort of Melanoma Trial

Prima BioMed enters new Material Transfer Agreement with Cytlimic

Prima announces new Product Candidate IMP761 – a LAG-3 Agonist Antibody